Genenta Science S.p.A. (GNTA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 15, 2021
| Name | Title | Pay | Year Born |
| Pierluigi Paracchi | Co-Founder, Chairman, Chief Executive Officer & GM | 0 | 1973 |
| Richard Slansky | Principal Financial & Accounting Officer | 0 | 1958 |
| Gianfranco De Nigris | Vice President Corporate Development | 0 | N/A |
| Bernard Rudolph Gentner | CO-Founder & Scientific Advisory Board Member | 0 | 1975 |
| Francesco Galimi | Chief Medical Officer, Head of Development & Director | 0 | 1968 |
| Luigi Naldini | Co-Founder & Chairman of Scientific Advisory Board | 0 | 1959 |
| Stefania Mazzoleni | Director of Program Development | 0 | 1982 |
| Barbara Regonini | Director of Finance | 0 | 1973 |
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.